Neurovision Pharma Gmbh

Mymeleon Ag

The Anti-inflammaging Company Ag

Hans-Lothar Arth

Markus Hossbach

Monika Krampert

Fabio Cavalli

Francesco Cavalli

The present invention relates to a visualized virtual agent configured to provide a visual response to a user, wherein the visualized virtual agent is further configured to provide an artificial physiological color change response to a user on the basis of one or more user-specific parameter, wherein the visualized virtual agent is configured to acquire user-specific data for at least one user-specific parameter using at least one sensor, the one or more user-specific parameter comprising activity data of the user and/or physio-psychological data of the user, and wherein the artificial physiological color change response is provided in response to monitored changes of the acquired user-specific data for the at least one user-specific parameter of the activity data of the user and/or the physio-psychological data of the user, the artificial physiological color change response comprising at least in part a color change of the visualized virtual agent.

Visualized virtual agent

The present invention relates to antisense-oligonucleotides having a length of at least 10 nucleotides, wherein at least two of the nucleotides are LNAs, their use as inhibitors of TGF-R signaling, pharmaceutical compositions containing such antisense-oligonucleotides and the use for prophylaxis and treatment of neurological, neurodegenerative, fibrotic and hyperproliferative diseases.

Antisense-oligonucleotides as inhibitors of TGF-R signaling

Growing community of inventors

Berlin, Germany

Hans-Lothar Arth